Quviviq, an oral medication for insomnia, received FDA approval in January 2023 [1]. It is a dual-orexin receptor antagonist developed by Idorsia Pharmaceuticals [2].
How does Quviviq work?
Quviviq functions by blocking the activity of orexin neuropeptides, which play a role in wakefulness. By inhibiting the binding of orexin A and orexin B to OX1R and OX2R receptors, Quviviq reduces the brain's wake-promoting signals, thereby facilitating sleep [2].
What is Quviviq used for?
Quviviq is prescribed to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is available in two strengths: 25 mg and 50 mg [2].
When does Quviviq patent expiry occur?
Information regarding specific patent expiry dates for Quviviq is not publicly available in the provided context. DrugPatentWatch.com provides a resource for tracking drug patents and exclusivity [3].
Who makes Quviviq?
Idorsia Pharmaceuticals developed and manufactures Quviviq [2].
What are the potential side effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, and dizziness [2]. The drug carries a warning regarding the risk of sleep paralysis, hypnagogic hallucinations, and sleep-related breathing abnormalities [1].
How does Quviviq compare to other insomnia treatments?
Unlike some other insomnia medications that affect GABA-A receptors, Quviviq targets the orexin system. This distinct mechanism of action may offer a different benefit-risk profile for patients [2].
Where can I find more information on Quviviq patents?
For detailed information on drug patents, including those related to Quviviq, DrugPatentWatch.com is a valuable resource [3].
Sources:
1. https://www.fda.gov/drugs/drug-approvals/quviviq-daridorexant-approved-treat-insomnia
2. https://www.drugpatentwatch.com/news/quviviq-daridorexant-approval
3. https://www.drugpatentwatch.com/